Publication | Closed Access
Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease
44
Citations
42
References
2016
Year
Cell-based Drug DeliveryTumor BiologyMedicinal ChemistryHistone DeacetylaseOncologyConsecutive Demasking VenturesPolymer-drug ConjugateMedicineDrug ActivationTumor TargetingAnti-cancer AgentCancer TreatmentTumour-associated ProteasePharmacologyRadiation OncologyCancer ResearchDrug DiscoveryCox-2 Positive Cells
An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.
| Year | Citations | |
|---|---|---|
2004 | 1.4K | |
1997 | 1.4K | |
2010 | 700 | |
2013 | 640 | |
2004 | 627 | |
Biocompatible Polymeric Nanoparticles Degrade and Release Cargo in Response to Biologically Relevant Levels of Hydrogen Peroxide Caroline de Gracia Lux, Shivanjali Joshi-Barr, Trung Van Nguyen, Journal of the American Chemical Society NanomedicineChemical EngineeringEngineeringPolymer-drug ConjugateNanobiotechnology | 2012 | 588 |
2006 | 574 | |
2013 | 514 | |
2011 | 436 | |
1998 | 399 |
Page 1
Page 1